drugset / Trial / NCT04224051
Metformin for Abdominal Aortic Aneurysm Growth Inhibition
RandomizedParallel-groupOpen-labelTreatment
Summary
A multi-centre population-based open-label randomized controlled trial with allocation concealment and blinded outcome assessment will examine if up to 2g metformin daily slows AAA growth in patients with small AAAs who do not have diabetes.
Timeline
- Start
- 2020-02-12
- Primary completion
- 2026-01
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 2 g | Oral |